BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

UBS Adjusts Price Target on Becton, Dickinson and Company to $265 From $260, Maintains Neutral Rating

11/05/2021 | 11:10am EDT


ę MT Newswires 2021
All news about BECTON, DICKINSON AND COMPANY
05/16BD Recognized by DiversityInc in Annual Ranking of Top US Companies for Diversity
AQ
05/13Embecta Fiscal Second-Quarter Results Fall on External Headwinds; Offers Downbeat Sales..
MT
05/12BD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Pl..
PR
05/12Becton, Dickinson and Company Launches Fully Automated, High-Throughput Infectious Dise..
CI
05/11TRANSCRIPT : Becton, Dickinson and Company Presents at Bank of America 2022 Healthcare Con..
CI
05/11Babson, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New C..
PR
05/11Babson Diagnostics, BD Expand Strategic Partnership to Advance Diagnostic Blood Collect..
CI
05/10INSIDER SELL : Becton Dickinson
MT
05/06Piper Sandler Adjusts Price Target on Becton Dickinson and Co. to $255 From $265, Maint..
MT
05/05BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 18 743 M - -
Net income 2022 1 746 M - -
Net Debt 2022 13 463 M - -
P/E ratio 2022 34,9x
Yield 2022 1,52%
Capitalization 71 580 M 71 580 M -
EV / Sales 2022 4,54x
EV / Sales 2023 4,30x
Nbr of Employees 75 000
Free-Float 77,6%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | BDX | US0758871091 | MarketScreener
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 251,10 $
Average target price 283,08 $
Spread / Average Target 12,7%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Joseph M. Smith Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY2.17%71 580
ABBOTT LABORATORIES-19.89%200 553
MEDTRONIC PLC0.12%142 552
BAXTER INTERNATIONAL INC.-15.98%37 432
HOYA CORPORATION-26.45%35 518
AMERISOURCEBERGEN CORPORATION18.09%32 871